As your company moves towards the regulatory submission of a marketing application to a health authority, there are many things to consider in your project planning. Among those is whom…
RsNLME is a collection of R packages & RShiny apps that allow scientists to run models using the Certara NLME engine directly from the R command line.
Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc., a global leader in biosimulation, today announced the acquisition of Integrated Nonclinical Development Solutions, Inc….
New therapeutics discovery and development for ocular diseases have been traditionally associated with a low probability of technical and regulatory success. The significant unmet medical needs for ocular diseases include…
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec. 13, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the…
Certara’s Japan team first met Dr. Kobuchi when he was studying Pharmacometrics at university for his PhD. He frequently attended our software training courses to learn Phoenix software. His proactive…
Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture of CDISC Controlled Terminology utilization.
Traditional mechanisms of drug action rely on the reversible, noncovalent interaction of a ligand with its biological target. On the other hand, a targeted covalent inhibitor (TCI) drug is designed…
Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ – October 25, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today…
© 2025 Certara. All Rights Reserved. | Privacy policy
